Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Reorganizes in Attempt to Focus on PGx, Metabolomics

NEW YORK, Jan. 20 (GenomeWeb News) - Clinical Data is consolidating its operations into two divisions in an attempt to focus efforts on its pharmacogenomics and metabolomics programs, the company announced today.

 

The new businesses will be called Clinical Data Molecular and Vital Diagnostics. Making up Clinical Data Molecular will be the operations acquired by the company in 2005: Genaissance (together with its Lark Technologies assets) and Icoria. The Vital Diagnostics division will consolidate the company's previously owned subsidiaries.

 

"Our emphasis will be to expand our menus of molecular services available to physicians, payors, pharmaceutical and biotechnology companies, and academic research organizations," CEO Israel Stein said in a statement.

 

The company said that the businesses comprising the Clinical Data Molecular unit generated $33 million for the 12 months ended Sept. 30. Vital Diagnostics revenues were about $53 million for that period.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.